L
Luke Alutuli
Publications - 1
Citations - 20
Luke Alutuli is an academic researcher. The author has contributed to research in topics: Insulin glargine & Biosimilar. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.
Papers
More filters
Journal ArticleDOI
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Brian Godman,Brian Godman,Brian Godman,Mainul Haque,Trudy Leong,Eleonora Allocati,Santosh Kumar,Salequl Islam,Jaykaran Charan,Farhana Akter,Amanj Kurdi,Amanj Kurdi,Amanj Kurdi,Carlos Vassalo,Muhammed Abu Bakar,Sagir Abdur Rahim,Nusrat Sultana,Farzana Deeba,M. A. Halim Khan,A. B.M.Muksudul Alam,Iffat Jahan,Zubair Mahmood Kamal,Humaira Hasin,Munzur-E-Murshid,Shamsun Nahar,M. E. Haque,Siddhartha Dutta,Jha Pallavi Abhayanand,Rimple Jeet Kaur,Godfrey Mutashambara Rwegerera,Renata Cristina Rezende Macedo do Nascimento,Isabella Piassi Godói,Mohammed Irfan,Adefolarin A. Amu,Patrick Matowa,Joseph Acolatse,Robert Incoom,Israel Abebrese Sefah,Jitendra Acharya,Sylvia Opanga,Lisper Wangeci Njeri,David Kimonge,Hye Young Kwon,Seung Jin Bae,Karen Koh Pek Khuan,Abdullahi Rabiu Abubakar,Ibrahim Haruna Sani,Tanveer Ahmed Khan,Shahzad Hussain,Zikria Saleem,Oliver Ombeva Malande,Thereza Piloya-Were,Rosana Gambogi,Carla Hernandez Ortiz,Luke Alutuli,Aubrey Chichonyi Kalungia,Iris Hoxha,Vanda Marković-Peković,Biljana Tubić,Guenka Petrova,Konstantin Tachkov,Ott Laius,András Harsányi,András Inotai,Arianit Jakupi,Svens Henkuzens,Kristina Garuoliene,Jolanta Gulbinovič,Magdalene Wladysiuk,Jakub Rutkowski,Ileana Mardare,Jurij Fürst,Stuart McTaggart,Sean MacBride-Stewart,Caridad Pontes,Caridad Pontes,Corinne Zara,Eunice Twumwaa Tagoe,Rita Banzi,Janney Wale,Mihajlo Jakovljevic,Mihajlo Jakovljevic +81 more
TL;DR: In this paper, the authors assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of insulin analogue biosimilars to benefit all key stakeholders.